↓ Skip to main content

18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start

Overview of attention for article published in European Journal of Nuclear Medicine and Molecular Imaging, August 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

twitter
2 X users
facebook
1 Facebook page

Citations

dimensions_citation
46 Dimensions

Readers on

mendeley
38 Mendeley
Title
18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start
Published in
European Journal of Nuclear Medicine and Molecular Imaging, August 2017
DOI 10.1007/s00259-017-3813-2
Pubmed ID
Authors

Ferdinand Seith, Andrea Forschner, Holger Schmidt, Christina Pfannenberg, Brigitte Gückel, Konstantin Nikolaou, Christian la Fougère, Claus Garbe, Nina Schwenzer

Abstract

The aim of the study was to evaluate if 18F-FDG-PET has the potential to detect complete responders to PD1-therapy in patients with unresectable metastasized melanoma two weeks after therapy initiation. Between September 2014 and May 2016, ten patients (four females; 65 ± 12 y) received a whole-body 18F-FDG-PET/MRI examination at three time points: Before therapy start (t0, base-line), two weeks (t1, study examination) and three months after treatment initiation (t2, reference standard). Therapy response was assessed with PET response criteria in solid tumors (PERCIST). Time to progression and overall survival (OS) were obtained for all patients. Three patients with partial metabolic response in PET at t1 turned out to have complete response at t2. No tumor relapse was observed in those patients so far (observation period: 265, 511 and 728 days, respectively). At t2, progressive metabolic disease (PMD) was seen in six patients from whom four showed PMD and two showed stable metabolic disease (SMD) at t1. OS in patients with PMD at t2 varied between 148 and 814 days. SMD at both t1 and t2 was seen in one patient, tumor progress was observed after 308 days. Our study indicates that whole-body 18F-FDG-PET might be able to reliably identify complete responders to PD1-therapy as early as two weeks after therapy initiation in stage IV melanoma patients. This might help to shorten therapy regimes and avoid unnecessary side effects in the future.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 38 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 21%
Researcher 6 16%
Student > Master 5 13%
Student > Bachelor 3 8%
Student > Doctoral Student 2 5%
Other 7 18%
Unknown 7 18%
Readers by discipline Count As %
Medicine and Dentistry 18 47%
Biochemistry, Genetics and Molecular Biology 3 8%
Immunology and Microbiology 2 5%
Chemistry 2 5%
Physics and Astronomy 2 5%
Other 3 8%
Unknown 8 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 September 2017.
All research outputs
#15,501,594
of 23,806,312 outputs
Outputs from European Journal of Nuclear Medicine and Molecular Imaging
#1,866
of 3,083 outputs
Outputs of similar age
#190,340
of 318,591 outputs
Outputs of similar age from European Journal of Nuclear Medicine and Molecular Imaging
#15
of 39 outputs
Altmetric has tracked 23,806,312 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,083 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 318,591 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.